Drug resistance in parasites: Can we stay ahead of the evolutionary curve?

Trends in Parasitology

Volumn 19, Issue 11, 2003, Pages 532-537

  Sibley, Carol Hopkins ^a   Hunt, Sonia Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; ANTIPARASITIC AGENT; METRONIDAZOLE; VACCINE;

ANTIBIOTIC RESISTANCE; BIOLOGICAL MONITORING; DRUG EFFICACY; DRUG USE; GENETIC DIFFERENCE; HUMAN; IMMUNE SYSTEM; IN VIVO STUDY; MOLECULAR EVOLUTION; NONHUMAN; PARASITOSIS; REDUCTION; REVIEW;

NEMATODA; PROTOZOA; VERMES;

EID: 0142196023     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.09.009     Document Type: Review

References (36)

1. Albonico M. Methods to sustain drug efficacy in helminth control programmes. Acta Trop. 86:(Suppl. 1-2):2003;233-242.
2. Trape J.F. The public health impact of chloroquine resistance in Africa. Am. J. Trop. Med. Hyg. 64:2001;12-17.
3. Newton P., et al. Fake artesunate in southeast Asia. Lancet. 357:2001;1948-1950.
4. Bloland, P.B. (2001) Drug Resistance in Malaria (4), WHO/CDS/CSR/DRS.
5. Ruebush T.K.I., et al. Practical aspects of in vivo antimalarial drug efficacy testing in the Americas. Am. J. Trop. Med. Hyg. 68:2003;391-397.
6. Newman R.D., et al. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop. Med. Int. Health. 8:2003;488-506.
7. Noedl H., et al. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 19:2003;175-181.
8. Milhous W.K., et al. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob. Agents Chemother. 27:1985;525-530.
9. Djimde A., et al. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:2001;257-263.
10. Baird J.K. Resurgent malaria at the millennium: control strategies in crisis. Drugs. 59:2000;719-743.
11. Nomura T., et al. Evidence for different mechanisms of chloroquine resistance in two Plasmodium species that cause human malaria. J. Infect. Dis. 183:2001;1653-1661.
12. Waller K.A., et al. Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter (PfCRT). J. Biol. Chem. 278:2003;33593-33601.
13. Land K.M., Johnson P.J. Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa. Drug Resist. Updat. 2:1999;289-294.
14. Borst P., Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu. Rev. Microbiol. 49:1995;427-460.
15. Drummelsmith J., et al. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol. Cell. Proteomics. 2:2003;146-155.
16. Dorsey G., et al. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala. Uganda. J. Infect. Dis. 183:2001;1417-1420.
17. Djimde A., et al. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet. 358:2001;890-891.
18. Kublin J.G., et al. Molecular markers for failure of sulfadoxine- pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185:2002;380-388.
19. Kublin J.G., et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 187:2003;1870-1875.
20. Hastings I.M. Malaria control and the evolution of drug resistance: an intriguing link. Trends Parasitol. 19:2003;70-73.
21. Hastings I. Response to: the puzzling links between malaria transmission level and drug resistance. Trends Parasitol. 19:2003;160-161.
22. Ariey F., Robert V. The puzzling links between malaria transmission and drug resistance. Trends Parasitol. 19:2003;158-160.
23. Tibayrenc M. Genetic epidemiology of parasitic protozoa and other infectious agents: the need for an integrated approach. Int. J. Parasitol. 28:1998;85-104.
24. Feng X., et al. Single-nucleotide polymorphisms and genome diversity in Plasmodium vivax. Proc. Natl. Acad. Sci. U. S. A. 100:2003;8502-8507.
25. Roper C., et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet. 361:2003;1174-1181.
26. Wootton J.C., et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature. 418:2002;320-323.
27. Marsh V.M., et al. Changing home treatment of childhood fevers by training shop keepers in rural Kenya. Trop. Med. Int. Health. 4:1999;383-389.
28. White N.J., Olliaro P.L. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol. Today. 12:1996;399-401.
29. Olliaro P., et al. Controlling malaria: challenges and solutions. Trop. Med. Int. Health. 6:2001;922-927.
30. Meuwissen T. The use of a medicated salt in an antimalaria campaign in West New Guinea. Trop. Geogr. Med. 16:1964;245-255.
31. Stich A., et al. Waking up to sleeping sickness. Trends Parasitol. 19:2003;195-197.
32. Legros D., et al. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect. Dis. 2:2002;437-440.
33. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health. 6:2001;849-854.
34. Hay S.I., et al. Malaria early warning in Kenya. Trends Parasitol. 17:2001;95-99.
35. Malakooti M.A., et al. Reemergence of epidemic malaria in the highlands of western Kenya. Emerg. Infect. Dis. 4:1998;671-676.
36. Pearce R.J., et al. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob. Agents Chemother. 47:2003;1347-1354.